Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes

Journal of Microencapsulation

Volumn 30, Issue 3, 2013, Pages 225-236

  Raza, Kaisar ^a   Katare, Om Prakash ^a   Setia, Arvind ^a   Bhatia, Amit ^a   Singh, Bhupinder ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Anthralin; Colloidal delivery; Compritol; FbD; Irritation; Phospholipid

Indexed keywords

DITHRANOL; LIPID; NANOCARRIER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; EMULSOME; MOUSE; NONHUMAN; PARTICLE SIZE; PATIENT COMPLIANCE; PSORIASIS;

ANIMALS; ANTHRALIN; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; EMULSIONS; HUMANS; MICE; NANOSTRUCTURES; PSORIASIS;

EID: 84874302972     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.717115     Document Type: Article

References (36)

1. Agarwal R, Katare OP, Vyas SP. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm, 2001;228: 43-52. (Pubitemid 32905364)
2. Amselem AS, Yogev A, Zawoznik E, Friedman D. 1994. Emulsomes, a novel drug delivery technology, Proceedings of the international symposium on the control and release of bioactive materials, Vol. 21, p. 1369.
3. Bhatia A, Raza K, Singh B, Katare OP. Phospholipid-based formulation with improved attributes of coal tar. J Cosmet Dermatol, 2009;8: 282-88.
4. British Pharmacopoeia (BP). 2008. British Pharmacopoeia Commission, Secretariat of Medicines and Healthcare Products Regulatory Agency, London, p. 2641.
5. Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet, 2003;42: 461-74. (Pubitemid 36649039)
6. Cuia F, Shia K, Zhanga L, Taoa A, Kawashima Y. Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J Control Rel, 2006;114: 242-50. (Pubitemid 44291843)
7. European Pharmacopoeia (Eur Ph 7.0). 2010. European Directorate for the Quality of Medicines, Council of Europe, Strasbourg, France, p. 2110.
8. Fluhr JW, Kuss O, Diepgen T, Lazzerini S, Pelosi A, Gloor M, Berardesca E. Testing for irritation with a multifactorial approach: Comparison of eight non-invasive measuring techniques on five different irritation types. Br J Dermatol, 2001;145: 696-703. (Pubitemid 33078338)
9. Ishii F, Nii T. Properties of various phospholipid mixtures as emulsifiers or dispersing agents in nanoparticle drug carrier preparations. Colloids Surf B Biointerfaces, 2005;41: 257-62. (Pubitemid 40312742)
10. Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Indian J Dermatol Venereol Leprol, 2010;76: 612-21.
11. Kato A, Ishibashi Y, Miyake Y. Effect of egg yolk lecithin on transdermal delivery of bunazosin hydrochloride. J Pharm Pharmacol, 1987;39: 399-400. (Pubitemid 17119501)
12. Kudsi S, Bersaques J De, Geerts ML, Remon JP, Muynck C De. Watermiscible dithranol cream in treatment of psoriasis. J Dermatolog Treat, 1991;2: 19-22.
13. Kumar R, Singh B, Bakshi G, Katare OP. Development of liposomal systems of finasteride for topical applications: Design, characterization, and in vitro evaluation. Pharm Dev Technol, 2007;12: 591-601.
14. Lewis GA, Mathieu D, Phan-Tan-Luu R, 1999. Pharmaceutical experimental design. 1st ed. New York, NY: Marcel Dekker.
15. Mahrle G. Dithranol. Clin Dermatol, 1997;15: 723-37.
16. Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol, 2005;27: 1-20.
17. Murthy RSR, Umrethia ML. Optimization of formulation parameters for the preparation of flutamide liposomes by 3(3) factorial 26 -terms logit model. Pharm Dev Technol, 2004;9: 1-9.
18. Mustakallio KK. Irritation and staining by dithranol (anthralin) and related compounds: I. Estimation with chamber testing and contact thermography. Acta Derm Venereol Suppl (Stockh), 1979;59: 125-32. (Pubitemid 10244734)
19. Mustakalio KK. Irritation, staining and antipsoriatic activity of 10-acyl analogue of anthralin. Br J Dermatol, 1981;105: 23-7.
20. Prins M, Swinkels OQ, Kolkman EG, Wuis EW, Hekster YA, van der Valk PG. Skin irritation by dithranol cream: A blind study to assess the role of the cream formulation. Acta Derm Venereol, 1998;78: 262-5. (Pubitemid 28328918)
21. Raza K, Negi P, Takyar S, Shukla A, Amarji B, Katare OP. Novel dithranol phospholipid microemulsion for topical application: Development, characterization and percutaneous absorption studies. J Microencapsul, 2011a;28: 190-9.
22. Raza K, Singh B, Mahajan A, Negi P, Bhatia A, Katare OP. Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. J Drug Target, 2011b;19: 293-302.
23. Schubert MA, Müller-Goymann CC. Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm, 2005;61: 77-86. (Pubitemid 41096691)
24. Schwartz JB, Connor RE, 1996. Optimization techniques in pharmaceutical formulation and processing. In: Banker GS, Rhodes CT, eds. Modern pharmaceutics. New York: Marcel Dekker. pp. 727-52.
25. Seth AK, Mishra A, Umrigar D. Topical liposomal gel of idoxuridine for the treatment of herpes simplex: Pharmaceutical and clinical implications. Pharm Dev Technol, 2004;9: 277-89. (Pubitemid 39166280)
26. Singh B, Ahuja N. Book review on ''Pharmaceutical Experimental Design''. Int J Pharm, 2000;195: 247-48.
27. Singh B, Ahuja N. Development of controlled release bucco-adhesive hydrophilc matrices of diltiazem hydrochloride: Optimization of bioadhesion, dissolution and diffusion parameters. Drug Develop Ind Pharm, 2002;28: 433-44.
28. Singh B, Dahiya M, Saharan V, Ahuja N. Optimizing drug delivery systems using ''Design of Experiments'' Part II: Retrospect and Prospects. Crit Rev Ther Drug Carrier Syst, 2005a;22: 215-92.
29. Singh B, Kapil R, Nandi M, Ahuja N. Developing oral drug delivery systems using formulation by design: Vital precepts, retrospect and prospects. Expert Opin Drug Deliv, 2011;8: 1341-60.
30. Singh B, Kaur S, Ahuja N. Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS PharmSciTech, 2006;7:E1-10.
31. Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using ''Design of Experiments'' Part 1: Fundamental aspects. Crit Rev Ther Drug Carrier Syst, 2005b;22: 27-106.
32. Singh B, Mehta G, Kumar R, Bhatia A, Ahuja N, Katare OP. Design, development and optimization of nimesulide-loaded liposomal systems for topical application. Curr Drug Del, 2005c;2: 143-53. (Pubitemid 40488624)
33. Singh B, Pahuja S, Kapil R, Ahuja N. Formulation development of oral controlled release tablets of hydralazine: Optimization of drug release and bioadhesive characteristics. Acta Pharm, 2009;59: 1-13.
34. United States Pharmacopeia (USP 34) and the National Formulary (NF 29). 2011. US Pharmacopeial Convention, United States, p. 1536.
35. Vyas SP, Gupta S. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target, 2007;15: 206-17. (Pubitemid 46562633)
36. Weller PJ, Newman CM, Middleton KR, Wicker SM. Stability of a novel dithranol ointment formulation, containing ascorbyl palmitate as an anti-oxidant. J Clin Pharm Ther, 1990;15: 419-23.